{"nctId":"NCT00004228","briefTitle":"Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma","startDateStruct":{"date":"2000-06"},"conditions":["Lymphoma"],"count":393,"armGroups":[{"label":"A0 (localized disease Stg I/II) Modified CCG BFM","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: cyclophosphamide","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: dexamethasone","Drug: doxorubicin hydrochloride","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: thioguanine","Drug: vincristine sulfate"]},{"label":"A1 (Disseminated, No CNS - CCG mod BFM w/out intens","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: cyclophosphamide","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: dexamethasone","Drug: doxorubicin hydrochloride","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: thioguanine","Drug: vincristine sulfate"]},{"label":"A2 (Disseminated, No CNS - CCG mod BFM w/ intens","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: cyclophosphamide","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: dexamethasone","Drug: doxorubicin hydrochloride","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: thioguanine","Drug: vincristine sulfate"]},{"label":"B2 (CNS+) NHL/BFM-95 w/intens delayed radiation therapy","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: cyclophosphamide","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: dexamethasone","Drug: doxorubicin hydrochloride","Drug: leucovorin calcium","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: thioguanine","Drug: vincristine sulfate","Radiation: radiation therapy"]},{"label":"B1 (Disseminated CNS- <Amend 7B) NHL/BFM-95 w/out intens","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: cyclophosphamide","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: dexamethasone","Drug: doxorubicin hydrochloride","Drug: leucovorin calcium","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: thioguanine","Drug: vincristine sulfate"]},{"label":"B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/intens","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: cyclophosphamide","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: dexamethasone","Drug: doxorubicin hydrochloride","Drug: leucovorin calcium","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: thioguanine","Drug: vincristine sulfate"]},{"label":"B1 (Disseminated CNS-) NHL/BFM-95 w/out intens","type":"EXPERIMENTAL","interventionNames":["Drug: asparaginase","Drug: cyclophosphamide","Drug: cytarabine","Drug: daunorubicin hydrochloride","Drug: dexamethasone","Drug: doxorubicin hydrochloride","Drug: leucovorin calcium","Drug: mercaptopurine","Drug: methotrexate","Drug: prednisone","Drug: thioguanine","Drug: vincristine sulfate"]}],"interventions":[{"name":"asparaginase","otherNames":["E.coli L-asparaginase","EC 3.5.2.2","colaspase","L-asnase","Elspar","Kidrolase","Crasnitin","Leunase","NSC#109229"]},{"name":"cyclophosphamide","otherNames":["Cytoxan","NSC #26271"]},{"name":"cytarabine","otherNames":["cytosine arabinoside","Ara-C","Cytosar","NSC #63878"]},{"name":"daunorubicin hydrochloride","otherNames":["daunomycin","rubidomycin","Cerubidine","NSC #82151"]},{"name":"dexamethasone","otherNames":["Decadron","Hexadrol","Dexone","Dexameth","NSC #34521"]},{"name":"doxorubicin hydrochloride","otherNames":["Adriamycin","NSC #123127"]},{"name":"leucovorin calcium","otherNames":["LCV","Wellcovorin","citrovorum factor","folinic acid","NSC #003590"]},{"name":"mercaptopurine","otherNames":["6-MP","Purinethol","6-mercaptopurine","NSC #000755"]},{"name":"methotrexate","otherNames":["MTX","amethopterin","Trexall","NSC #000740"]},{"name":"prednisone","otherNames":["Deltasone","Meticorten","Orasone","Liquid Pred","Pediapred","Sterapred","NSC #010023"]},{"name":"thioguanine","otherNames":["6-thioguanine","2-amino-1,7-dihydro-6H-purine-6-thione","WR-1141","Tabloid","Lanvis","NSC # 751"]},{"name":"vincristine sulfate","otherNames":["Oncovin","VCR","LCR","NSC #67574"]},{"name":"radiation therapy","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"DISEASE CHARACTERISTICS:\n\n* Newly diagnosed disseminated lymphoblastic lymphoma or localized lymphoblastic lymphoma\\*\n\n  * Less than 25% tumor cells in the bone marrow\n  * Previously untreated (prior intrathecal cytarabine allowed if protocol therapy begins within 72 hours)\n  * Stage III or IV disease\n* NOTE: \\*Localized lymphoblastic lymphoma is closed to accrual as of 10/2005\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 1 to 30\n\nPerformance status:\n\n* Not specified\n\nLife expectancy:\n\n* Not specified\n\nHematopoietic:\n\n* Not specified\n\nHepatic:\n\n* Not specified\n\nRenal:\n\n* Not specified\n\nCardiovascular:\n\n* Adequate cardiac function\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* See Disease Characteristics\n\nEndocrine therapy:\n\n* Emergency steroid therapy (if required) must be started within 72 hours prior to protocol therapy\n\nRadiotherapy:\n\n* Emergency radiotherapy (if required) must be started within 72 hours prior to protocol therapy\n\nSurgery:\n\n* Not specified\n\nOther:\n\n* No other prior therapy except for emergency treatment of airway obstruction and/or superior vena cava syndrome","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","maximumAge":"30 Years","stdAges":["CHILD","ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Event-free Survival","description":"Assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause. Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"82","spread":null},{"groupId":"OG002","value":"80","spread":null},{"groupId":"OG003","value":"63","spread":null},{"groupId":"OG004","value":"82","spread":null},{"groupId":"OG005","value":"84","spread":null},{"groupId":"OG006","value":"90","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Overall Survival as Assessed by Time to Death","description":"Overall survival will be computed by measuring the rate of deaths during induction due primarily to treatment toxicity and cumulative incidence of toxic deaths in induction or deaths in remission overall and separately for treatment groups defined by the two design factors.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"81","spread":null},{"groupId":"OG004","value":"85","spread":null},{"groupId":"OG005","value":"85","spread":null},{"groupId":"OG006","value":"92","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":56},"commonTop":["Hemoglobin (Hgb)","Leukocytes (total WBC)","Platelets","SGPT (ALT)","Febrile neutropenia"]}}}